MX376337B - Uso de inositoles fosfato para la fabricación de un medicamento para el tratamiento y/o prevención de una enfermedad asociada al fallo renal en un sujeto que padece fallo renal. - Google Patents

Uso de inositoles fosfato para la fabricación de un medicamento para el tratamiento y/o prevención de una enfermedad asociada al fallo renal en un sujeto que padece fallo renal.

Info

Publication number
MX376337B
MX376337B MX2015013088A MX2015013088A MX376337B MX 376337 B MX376337 B MX 376337B MX 2015013088 A MX2015013088 A MX 2015013088A MX 2015013088 A MX2015013088 A MX 2015013088A MX 376337 B MX376337 B MX 376337B
Authority
MX
Mexico
Prior art keywords
renal failure
treatment
inositole
medicine
phosphate
Prior art date
Application number
MX2015013088A
Other languages
English (en)
Other versions
MX2015013088A (es
Inventor
Reynés Miquel David Ferrer
Amengual Bernat Isern
Pieter H Joubert
Joan Perelló Bestard
Roca Carolina Salcedo
Original Assignee
Laboratoris Sanifit S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoris Sanifit S L filed Critical Laboratoris Sanifit S L
Publication of MX2015013088A publication Critical patent/MX2015013088A/es
Publication of MX376337B publication Critical patent/MX376337B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso para el tratamiento de pacientes con fallo renal en forma de liberación controlada de un derivado de con enlaces C-O-P. Además comprende el uso de dichos compuestos derivados junto con otros principios activos, que particularmente se pueden seleccionar de la lista que comprende un calcimimético, vitamina, quelante de fosforo, tiosulfato, bifosfonato, pirofosfato, citrato, un diurético, antihipertensivo y aniticolesterolémico.
MX2015013088A 2013-03-15 2014-03-14 Uso de inositoles fosfato para la fabricación de un medicamento para el tratamiento y/o prevención de una enfermedad asociada al fallo renal en un sujeto que padece fallo renal. MX376337B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201330383A ES2495666B1 (es) 2013-03-15 2013-03-15 Uso de derivados con enlaces c-o-p en pacientes con fallo renal
PCT/ES2014/070184 WO2014140402A1 (es) 2013-03-15 2014-03-14 Uso de derivados con enlaces c-o-p en pacientes con fallo renal

Publications (2)

Publication Number Publication Date
MX2015013088A MX2015013088A (es) 2016-04-18
MX376337B true MX376337B (es) 2025-03-07

Family

ID=50478876

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013088A MX376337B (es) 2013-03-15 2014-03-14 Uso de inositoles fosfato para la fabricación de un medicamento para el tratamiento y/o prevención de una enfermedad asociada al fallo renal en un sujeto que padece fallo renal.

Country Status (11)

Country Link
EP (1) EP2974714B1 (es)
JP (2) JP6571538B2 (es)
CN (2) CN114010649A (es)
AU (2) AU2014229971B2 (es)
BR (1) BR112015023509A2 (es)
CA (1) CA2906264C (es)
ES (2) ES2495666B1 (es)
HK (1) HK1220898A1 (es)
MX (1) MX376337B (es)
RU (1) RU2725626C2 (es)
WO (1) WO2014140402A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016013737A1 (de) 2016-11-17 2018-05-17 WindplusSonne GmbH Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe
JP7118635B2 (ja) * 2017-12-20 2022-08-16 Ｅａファーマ株式会社 医薬用組成物
EP3556728A1 (en) * 2018-04-16 2019-10-23 Croda Denmark A/S Organically modified mineral micro-particles, methods of preparing the same and uses thereof
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3833665B1 (en) 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
AU2018445164B2 (en) 2018-10-11 2025-05-29 Vifor (International) Ltd. Inositol phosphates for the treatment of ectopic calcification
CN113365636A (zh) * 2019-01-30 2021-09-07 萨尼菲特治疗有限公司 用于增加组织灌注的磷酸肌醇化合物
EP3818983A1 (en) * 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
EP4015494A1 (en) * 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330979A (en) * 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
SU1435255A1 (ru) * 1986-10-20 1988-11-07 Московский медицинский стоматологический институт им.Н.А.Семашко Способ восстановлени противотромбогенной активности сосудистой стенки у кардиологических больных
IT1306133B1 (it) * 1999-04-22 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina ed un inositolfosfato, utilequale integratore dietetico o medicamento.
DE29910454U1 (de) * 1999-06-10 1999-09-23 Vitasyn GmbH, 10789 Berlin Mittel zur Therapie von Hyperphosphatämie
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.

Also Published As

Publication number Publication date
AU2019201988A1 (en) 2019-04-11
JP6863618B2 (ja) 2021-04-21
RU2725626C2 (ru) 2020-07-03
AU2019201988B2 (en) 2021-04-08
ES3030485T3 (en) 2025-06-30
CA2906264A1 (en) 2014-09-18
AU2014229971B2 (en) 2019-04-04
AU2014229971A1 (en) 2015-11-05
BR112015023509A2 (pt) 2017-07-18
ES2495666A2 (es) 2014-09-17
ES2495666R1 (es) 2014-10-30
HK1220898A1 (zh) 2017-05-19
RU2015139225A (ru) 2017-04-24
EP2974714B1 (en) 2025-05-07
MX2015013088A (es) 2016-04-18
JP6571538B2 (ja) 2019-09-04
WO2014140402A1 (es) 2014-09-18
ES2495666B1 (es) 2015-08-10
CN105611913A (zh) 2016-05-25
JP2019206580A (ja) 2019-12-05
CA2906264C (en) 2021-05-11
CN114010649A (zh) 2022-02-08
EP2974714A1 (en) 2016-01-20
JP2016514119A (ja) 2016-05-19

Similar Documents

Publication Publication Date Title
MX376337B (es) Uso de inositoles fosfato para la fabricación de un medicamento para el tratamiento y/o prevención de una enfermedad asociada al fallo renal en un sujeto que padece fallo renal.
DOP2017000272A (es) Métodos de diagnóstico para tratamiento con linfocitos t
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
JP2014515038A5 (es)
MY186106A (en) Diagnosis, prevention and treatment of diseases of the joint
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
TN2015000371A1 (en) Substituted imidazopyridazines
PL3003285T3 (pl) Stała farmaceutyczna postać dawkowania do uwalniania co najmniej dwóch substancji czynnych w jamie ustnej
PH12015501940A1 (en) Dihydropyridazine-3,5-dione derivative
MX2016013236A (es) Formulacion inmunosupresora.
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
PH12016501095A1 (en) Gabapentinoids and sigma receptor ligands combinations
AR091706A1 (es) Formulaciones de laquinimod sin agentes alcalinizantes
PH12015502023A1 (en) Guanidinobenzoic acid ester compound
CO2017002813A2 (es) Derivados estabilizados de adrenomedulina y uso de los mismos
EA201500376A1 (ru) Композиция для ухода за полостью рта
MX2016001422A (es) Composicion farmaceutica de fingolimod.
BR112014027653A2 (pt) formulações para a liberação dos ingredientes ativos
IN2014MN01382A (es)
PH12015502727A1 (en) Methods and compositions for enhancing cognitive performance
MX2019010229A (es) Composicion para la liberacion controlada de sustancias fisiologicamente activas y proceso para su preparacion.
PH12018500463A1 (en) Solid soluble ferric pyrophosphate formulations, kits, and methods using the same
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif

Legal Events

Date Code Title Description
FG Grant or registration